Evidence map›Paper›PMID 26707937›Full record

ArticleToxicology and applied pharmacology2016

Application of small RNA sequencing to identify microRNAs in acute kidney injury and fibrosis.

Kathryn L Pellegrini, Cory V Gerlach, Florin L Craciun, Krithika Ramachandran, Vanesa Bijol, Haydn T Kissick, Vishal S Vaidya

Open access · greenAbstract read
In one paragraph

Article in Toxicology and applied pharmacology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers.

0numbers the graph read from it
0cells of the map it votes in
32citing papers in PubMed
1.9field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

32 citing papers in PubMed, 60 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Understanding Cisplatin Pharmacokinetics and Toxicodynamics to Predict and Prevent Kidney Injury.The Journal of pharmacology and experimental therapeutics · 2024
    Review
  5. Review
  6. Article
  7. Article
  8. MicroRNAs in kidney injury and disease.Nature reviews. Nephrology · 2022
    Review
  9. Article
  10. Article
  11. Review
  12. Article
  13. Article
  14. Review
  15. Article
  16. Epigenetics in kidney diseases.Advances in clinical chemistry · 2021
    Review
  17. Article
  18. Article
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

Kathryn L PellegriniDepartment of Medicine, Renal Division, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.
Cory V GerlachDepartment of Medicine, Renal Division, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA; Department of Environmental Health, Harvard T.H. Chan School of Public Health, Boston, MA, USA; Laboratory of Systems Pharmacology, Harvard Program in Therapeutic Sciences, Harvard Medical School, Boston, MA, USA.
Florin L CraciunDepartment of Medicine, Renal Division, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.
Krithika RamachandranDepartment of Medicine, Renal Division, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.
Vanesa BijolDepartment of Pathology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.
Haydn T KissickDepartment of Surgery, Urology Division, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA.
Vishal S VaidyaDepartment of Medicine, Renal Division, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA; Department of Environmental Health, Harvard T.H. Chan School of Public Health, Boston, MA, USA; Laboratory of Systems Pharmacology, Harvard Program in Therapeutic Sciences, Harvard Medical School, Boston, MA, USA. Electronic address: vvaidya@bwh.harvard.edu.
Harvard University · USBrigham and Women's Hospital · US

Funding

Role of SMOC2 in Kidney FibrosisR01ES017543 · NIEHS · BRIGHAM AND WOMEN'S HOSPITAL · PI VAIDYA, VISHAL S. · 2011 to 2021
$3.9M
Role of SMOC2 in Kidney FibrosisR56ES017543 · NIEHS · BRIGHAM AND WOMEN'S HOSPITAL · PI VAIDYA, VISHAL S. · 2016 to 2016
$213k
NIEHS NIH HHS R01 ES017543NIEHS NIH HHS R56 ES017543
6 · The paper itself

Abstract

Establishing a microRNA (miRNA) expression profile in affected tissues provides an important foundation for the discovery of miRNAs involved in the development or progression of pathologic conditions. We conducted small RNA sequencing to generate a temporal profile of miRNA expression in the kidneys using a mouse model of folic acid-induced (250mg/kgi.p.) kidney injury and fibrosis. From the 103 miRNAs that were differentially expressed over the time course (>2-fold, p<0.05), we chose to further investigate miR-18a-5p, which is expressed during the acute stage of the injury; miR-132-3p, which is upregulated during transition between acute and fibrotic injury; and miR-146b-5p, which is highly expressed at the peak of fibrosis. Using qRT-PCR, we confirmed the increased expression of these candidate miRNAs in the folic acid model as well as in other established mouse models of acute injury (ischemia/reperfusion injury) and fibrosis (unilateral ureteral obstruction). In situ hybridization confirmed high expression of miR-18a-5p, miR-132-3p and miR-146b-5p throughout the kidney cortex in mice and humans with severe kidney injury or fibrosis. When primary human proximal tubular epithelial cells were treated with model nephrotoxicants such as cadmium chloride (CdCl

Indexed as

Acute Kidney InjuryAnimalsFibrosisFolic AcidIn Situ HybridizationKidney Tubules, ProximalMaleMiceMice, Inbred BALB CMicroRNAsRNAFolic AcidMicroRNAsRNAFolic AcidKidney FibrosisKidney ToxicitymiRNAsSmall RNA Sequencing

Identifiers

PMID26707937
PMCPMC4912473
OpenAlexW2200226739

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.